May 29, 2020 -- Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to investigate cancer treatment technologies.
The partnership will study a new class of antitumor agents, including lead anticancer drug candidate WP1244. The new drug candidate can cross the blood-brain barrier and is a DNA binding agent more potent than daunorubicin, a clinical chemotherapeutic agent used to prevent tumor cell growth. The biologic is of a novel class of DNA binding agents and was designed at MD Anderson using modular drug design strategies.
Dr. Waldemar Priebe, founder of CNS and a professor of medicinal chemistry at MD Anderson, will serve as the project's principal investigator. The partnership aligns with MD Anderson's conflict of interest policies, according to CNS.